Skip to main content
OpenTrials

Clinical trial condition

HER-2 Positive Breast Cancer

Explore clinical trials studying HER-2 Positive Breast Cancer. Study availability and eligibility vary by location and protocol.

19 public trials 1 recruiting study
Refine in advanced search Browse all conditions

HER-2 Positive Breast Cancer trial results

Recruiting

Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

NCT07506876

Conditions
Breast Cancer - Infiltrating Ductal Carcinoma, HER-2 Positive Breast Cancer
Locations
  • Legacy Mount Hood Medical Center Gresham, Oregon, United States
  • Legacy Good Samaritan Medical Center Portland, Oregon, United States
  • Legacy Meridian Park Medical Center Tualatin, Oregon, United States
  • Legacy Salmon Creek Medical Center Vancouver, Washington, United States
View Trial Details
Completed

HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1

NCT01565200

Conditions
Breast Diseases, Breast Neoplasms, HER-2 Positive Breast Cancer, +4 more
Locations
  • Universitair Ziekenhuis Antwerpen (UZA) Antwerp, Edegem, Belgium
  • Institut Jules Bordet Brussels, Belgium
  • Vrije Universiteit Amsterdam (VUMC) Amsterdam, Netherlands
  • University Medical Center Groningen (UMCG) Groningen, Netherlands
View Trial Details
Completed

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

NCT02492711

Conditions
HER-2 Positive Breast Cancer, Metastatic Neoplasm, Neoplasm Metastasis, +4 more
Locations
  • Ironwood Cancer & Research Center Chandler, Arizona, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Western Regional Medical Center, Inc. Goodyear, Arizona, United States
  • East Valley Hematology And Oncology Burbank, California, United States
View all 167 locations
View Trial Details
Completed

A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer

NCT02488564

Conditions
HER-2 Positive Breast Cancer
Locations
  • IRST Oncologia medica Meldola, FC, Italy
  • Oncologia Medica AOU Ferrara Ferrara, FE, Italy
  • Oncologia Medica, Policlinico di Modena Modena, MO, Italy
  • Oncologia Medica Ospedale Guglielmo da Saliceto Piacenza, PC, Italy
View Trial Details
Completed

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

NCT02675231

Conditions
HER-2 Positive Breast Cancer, Hormone Receptor Positive Breast Cancer
Locations
  • Comprehensive Blood and Cancer Center Bakersfield, California, United States
  • St Jude Medical Center Fullerton, California, United States
  • TRIO - Translational Research in Oncology-US, Inc. Los Angeles, California, United States
  • USC Norris Cancer Hospital Los Angeles, California, United States
View all 93 locations
View Trial Details
Completed

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

NCT01340430

Conditions
Disease Attributes, Disease Progression, HER-2 Positive Breast Cancer, +3 more
Locations
  • Istituto Nazionale per La Ricerca sul Cancro (IST) Genoa, Ge, Italy
  • Ospedale S. Maria della Misericordia - Oncologia Medica Perugia, PG, Italy
  • Fondazione del Piemonte per l'Oncologia - IRCC di Candiolo Candiolo, TO, Italy
  • Ospedale Ostetrico Ginecologico S. Anna Di Torino - Oncologia Medica Torino, To, Italy
View Trial Details
Completed

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

NCT00788931

Conditions
Breast Diseases, Breast Neoplasms, HER-2 Positive Breast Cancer, +5 more
Locations
  • Novartis Investigative Site Mobile, Alabama, United States
  • Novartis Investigative Site Woodville, South Australia, Australia
  • Novartis Investigative Site Brussels, Belgium
  • Novartis Investigative Site Liège, Belgium
View Trial Details

Related conditions